<div>
  <ul>
    <li>
      <p>
        <b>BenevolentAI</b>
        ’s repurposed drug for Covid-19 has been granted the FDA’s Emergency Use Authorization. 
      </p>
    </li>
    <li>
      <p>
        <b>Exscientia</b>
         has been screening more than 15,000 drugs (comprising some approved and others clinically ready) to assess their effectiveness against Covid-19.
      </p>
    </li>
    <li>
      <p>
        <b>Insilico Medicine </b>
        launched COVIDomic, a system for Covid-19 basic and clinical research.
      </p>
    </li>
    <li>
      <p>
        <b>AbCellera</b>
         has discovered antibody treatment for Covid-19, Bamlanivimab, using its AI-powered discovery platform, which received the FDA’s Emergency Use Authorization. 
      </p>
    </li>
    <li>
      <p>
        Google’s 
        <b>DeepMind</b>
         used its AlphaFold AI platform to publish predictions of protein structures associated with the virus.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


COVID19-IMPACT

<h3>Disruptors’ value proposition comes from their specialization and unique technology</h3><p>Both artificial intelligence (AI) Software-as-a-Service (SaaS) companies and AI-driven biotechnology startups often collaborate with big pharma companies to leverage from the benefits of synergy or due to the lack of funding/expertise to develop drugs in-house. Given that most big pharma companies have also integrated AI into their drug development process in some form, disruptors’ value proposition comes from their specialization and unique technologies.</p>

<p>The AI drug discovery industry consists of:</p><p><strong>AI SaaS companies</strong>: A large number of startups in the AI drug discovery space operate as AI SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies. These pure play startups often specialize in a specific stage of the drug discovery process, and have not expanded into latter stages of drug development.</p><p><strong>AI drug discovery and development companies</strong>: Majority of the well funded startups in the AI drug discovery space operate as drug discovery and development companies. These are biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs and also collaborate with pharma companies to develop certain drugs.</p><p><strong>Pharma incumbents</strong>: Large pharma companies operate in this space through collaborations with AI startups or tech companies or by developing in-house AI capabilities.</p><p><strong>Tech incumbents</strong>: Tech companies which are known for their strong AI capabilities have also entered the industry and offer machine learning tools to support drug discovery. Tech incumbents simply offer ML tools and are not specialized in any particular segment. Hence, they are not included in the market map.</p><p>Over 90% of the startups are at the seed/early stages. Most AI SaaS platform operators are yet to achieve stable revenue despite collaborations with pharma companies. AI biotechnology startups have not commercialized their drug with only a few reaching the clinical trial stage.</p>

<div>
  <p>
    Massachusetts-based Valo Health operates Opal, an AI-driven drug discovery platform aimed at predicting molecules that can be used as drugs against new diseases by leveraging a dataset of more than 125-million-patient-years combined from thousands of sources. Valo’s initial focus is to develop a pipeline of candidates for cancer, cardiovascular diseases, and neurodegeneration.  
  </p>
  <p>
    The company has four cancer therapy programs in its pipeline, all of which are in the early stages of drug development. These include a synthetic lethal cancer metabolism approach that targets blood cancer and solid tumor malignancies without toxic side effects that are common among other treatments. Founded in 2018, the company has emerged as one of the most-highly funded companies in the AI drug discovery space. In March 2021, the company raised USD 110 million in extended Series B financing, bringing its total funding up to USD 450 million. Valo intends to use the proceeds to support the company’s therapeutic programs and accelerate further development of the Opal Computational Platform. 
  </p>
</div>


Valo Health

<div>
  <p>
    Based in Hong Kong, Insilico Medicine is an AI drug discovery company focused on three areas of drug discovery and development: disease target identification, generation of synthetic biology and novel molecules data, and predicting clinical trial outcomes. 
  </p>
  <p>
    Founded in 2014, the company's key focus area is anti-aging interventions, however, there is also a therapeutic focus on areas such as oncology, dermatology, metabolic diseases, neuroscience, and rare diseases. Nearly a quarter of the company’s research and development (R&D) budget is committed toward aging diseases. 
  </p>
  <p>
    The company collaborates with pharma companies and also has its own pipeline of small molecules targeting many disease areas which the company aims to license to pharma players later. The company also provides several customer-facing tools for registered users, such as Young.AI and Aging.AI, which help to measure multiple predictors and biomarkers of aging.
  </p>
  <p>
    Insilico’s CEO remains bullish on the business potential of the Asian region and is actively pursuing collaborations with Chinese pharmaceutical companies. The company recently entered into partnerships with a few Chinese companies—GenFleet Therapeutics, Westlake Pharma, Usynova Pharmaceuticals, BioNova Pharmaceuticals, 4B Technologies, and Huadong Medicine—and US-based companies—Gray Matter and PAQ Therapeutics—to develop small molecule therapeutics for Covid-19, cancer, autoimmune diseases, specific hematologic malignancies and neurological diseases. It also directed its focus on proteolysis targeting chimera (PROTACs) therapeutics by entering into an R&D partnership with US-based Arvinas in August 2021. 
  </p>
  <p>
    In a landmark achievement, Insilico announced in September 2019 that by using its AI platform, it was able to discover a new lead compound for idiopathic pulmonary fibrosis (IPF) in just 46 days compared to the two-to-three-year timespan required for traditional drug discoveries. The company also completed the entire preclinical stage, from the earliest stages of identifying potential targets, in a record time of 18 months. This breakthrough, announced in February 2021, was a catalyst for the company’s latest Series C funding round in June 2021 in which it raised USD 255 million, bringing its total funds raised to USD 310 million. The funds will be mainly used to initiate human trials on the lead candidate, to be commenced by the end of 2021. The company is in talks to go public by the end of the year to raise USD 300 million, as reported by Bloomberg in July 2021. 
  </p>
</div>


Insilico Medicine

<div>
  <p>
    Nimbus Therapeutics is a biotechnology company designing small molecule compounds targeted at various diseases. It utilizes the chemical simulation computational platform built by co-founder Schrödinger Inc., which incorporates artificial intelligence and machine learning, and co-develops drugs by partnering with pharma companies. Its pipeline includes programs in metabolic diseases, cancer, and immune-inflammatory disorders. 
  </p>
  <p>
    It is currently developing six targets, of which one is in the clinical stage and another in the preclinical stage, while others remain at the discovery stage. Its pharma partners include Roche’s Genentech, Celgene, and Gilead. The company has plans to conduct multiple Phase 2 studies on its novel allosteric TYK2 inhibitor in 2021 and 2022. Additionally, Nimbus also expects to conduct a first-in-human study of its HPK1 inhibitor candidate in the latter part of 2021, which will be carried out on cancer patients with solid tumors. The company will also initiate investigational new drug (IND)-enabling studies on two novel agents in 2022.
  </p>
  <p>
    The company raised USD 105 million in a private financing round in July 2021 which brought the company’s total funding to date to USD 302 million. The funding will be used for the development and advancement of the company’s drug pipeline.
  </p>
</div>


Nimbus Therapeutics

<div>
  <p>
    Deep Genomics is a Canadian biotechnology company that has developed an AI and deep learning platform called the AI Workbench that uses terabytes of genetic data to precisely discover Ribonucleic acid (RNA) therapeutic targets. 
  </p>
  <p>
    The company claims programmable RNA therapeutics have significant potential in treating genetic diseases. Deep Genomics uses AI in every stage of drug development, from designing novel candidates to animal models and the company claims 70% of its research projects have resulted in a therapeutic lead and its programs have advanced from target discovery to drug candidate in less than a year.
  </p>
  <p>
    The company has 11 therapeutic programs, 10  of which are in the discovery stage while one has reached the target identification stage. This pipeline includes a drug candidate for Wilson disease—a rare and potentially fatal genetic disorder—which was identified in September 2019 and is regarded as the first-ever drug candidate discovery with the use of AI. The company  aims to advance this as the first drug candidate to the clinical trial stage. 
  </p>
  <p>
    In July 2021, Deep Genomics raised a USD 180 million Series C funding round to scale its pipeline to up to 30 drug candidates and expand AI Workbench to support the discovery of novel therapies for common diseases. The company has raised an aggregate of USD 236.4 million in private investments since its inception in 2015.
  </p>
</div>


Deep Genomics

<div>
  <p>
    Cellarity was founded by Flagship Pioneering, a venture capital firm that invests in the life sciences sector. By combining network biology, artificial intelligence (AI), and technology, Cellarity has created a drug discovery platform that develops drugs by studying and altering cell behavior. The company aims to be a drug discovery and development company with its own pipeline. It is also planning to work with partners to accelerate drug development.
  </p>
  <p>
    The company claims to be the first to pursue drug discovery based on understanding cell behavior, which aims to create medicine by targeting the full cellular and molecular complexity of diseases. The ability to do so should help the company significantly improve the success rate and speed of drug discovery. The startup claims that in just less than a year, it has been able to identify “nearly a dozen” lead drug candidates with in vivo proof-of-concept across multiple therapeutic areas.
  </p>
</div>


Cellarity

<div>
  <p>
    Pharnext is a French biotechnology company that aims to discover and develop new therapeutic solutions using what it calls the Pleotherapy approach, a combination of low doses of existing drugs to develop treatments by matching the properties of drug combinations with specific diseases. The company focuses on neurodegenerative and metabolic diseases, from research through to clinical development (until the end of Phase II trials), and then licenses the drugs to industrial partners.
  </p>
  <p>
    Pharnext has two drugs in its research and development (R&D) pipeline: 1) it is planning a final Phase III clinical trial of its investigational therapy PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), which is set to begin early next year. This is carried out with guidance from the US Food and Drug Administration (FDA), 2) PXT864 is a therapy at phase II for the treatment of Alzheimer’s disease. For the year-end as of December 31, 2019, Pharnext reported a 9.3% YoY growth in net losses to EUR 23.3 million (around USD 26.1 million) based on total income of EUR 3.6 million (around USD 4 million, down 47.1% YoY).
  </p>
</div>


Pharnext

<div>
  <p>
    Frontier Medicines is a biotechnology startup that is engaged in developing treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable by leveraging artificial intelligence and machine learning (AI & ML) technologies. 
  </p>
  <p>
    The company operates its proprietary chemoproteomic platform which entails an approach based on the interaction of small molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 100,000 novel binding pockets (hotspots). The platform’s AI & ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation. 
  </p>
  <p>
    The company entered into a partnership with AbbVie In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins. 
  </p>
  <p>
    Founded in 2018, the company currently has four wholly-owned therapeutic programs and two AbbVie partnered programs in its pipeline. All programs are in their discovery stage with a focus on oncology and immunology targets.  The company’s lead program is the KRASG12C (both activated and inactivated forms) which focuses on treating different cancer types including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC). It claims its technology will allow it to advance quickly from target identification to lead generation. 
  </p>
  <p>
    In July 2021, the company raised USD 88.5 million in a Series B funding round which brought its total funds raised to date to USD 155.5 million. The proceeds from the latest round were earmarked for advancing the company’s drug pipeline and expanding operations in Boston where its new facility will complement the company’s headquarters in California. 
  </p>
</div>


Frontier Medicines

<div>
  <p>
    BlackThorn Therapeutics is a biotechnology company focused on developing targeted medicines to treat central nervous system disorders. It does so with the use of its proprietary computational psychiatry platform that leverages artificial intelligence (AI) technologies. Its approach is to understand patients by using its proprietary brain imaging and functional assessment tools, identifying key receptors in dysregulated brain circuits as pipeline targets, developing brain-based biomarkers, and leveraging the power of AI and machine learning to generate insights into drug discovery and development. The company claims to have built the largest library of clinical neurobiological data.
  </p>
  <p>
    The company has three drug candidates in its pipeline with one of them focused on anxiety disorders at the Phase II clinical trial stage. In June 2019, the company raised USD 76 million in Series C financing which the company will use to develop its personalized medicines for the treatment of mental health disorders.
  </p>
</div>


BlackThorn Therapeutics

<div>
  <p>
    BioAge Labs is a biotechnology company that develops therapies to treat aging and aging-related diseases with the aim of extending the human lifespan. It has developed a systems biology and machine learning platform to leverage its own datasets (collected from human blood samples and medical records) to identify and map the key biological pathways that impact human longevity.
  </p>
  <p>
    Its current pipeline includes the BGE-175, a licensed clinical-stage therapy to treat immune aging in older patients hospitalized with Covid-19. The company had recently generated preclinical data that showed 100 percent survival in a preclinical model of the SARS 1 virus and believes the therapy will prove to be as effective in treating Covid-19. In addition to this, the company entered into a global license agreement with Taisho Pharmaceutical Co., Ltd, Tokyo (in April 2020) to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase to ameliorate multiple diseases of aging (called BGE-117).
  </p>
</div>


BIOAGE LABS

<div>
  <p>
    Neuron23 is engaged in developing precision medicine for neurological and immunological diseases. The company utilizes its artificial intelligence (AI)-enabled drug and biomarker discovery platforms to accelerate the drug development process. It currently has five small molecule candidates in its pipeline, all of which are at the early stages of drug development. Neuron23 was founded in 2018 through an innovative partnership with Origenis, a biotechnology company based in Germany. 
  </p>
  <p>
    In December 2020, the company emerged from stealth, raising a combined USD 113.5 million in Series A and B financing. The proceeds will be used to expand its AI drug discovery platform and advance the development of Neuron23’s drug pipeline focused on neurodegenerative diseases and immune disorders. The company plans to advance between two and three drug candidates in the pipeline into the clinical trial stage within the next two years. 
  </p>
</div>


Neuron23

<div>
  <p>
    Standigm develops novel AI-driven therapeutics using its early-stage drug discovery workflow AI to generate lead compounds. 
  </p>
  <p>
    The company’s technology incorporates active data parsing of raw biomedical data, AI modeling of the organized data with meaningful insights, and biological interpretation of how the drug compounds can impact humans. This also allows the best compounds to be chosen for testing and development, thus expediting the drug discovery process. The company claims that it can complete its research process within seven months. 
  </p>
  <p>
    Standigm’s platforms include Standigm ASK for target discovery, Standigm BEST for lead selection, and Standigm Insight for drug repurposing. The company has 22 drug candidates in its pipeline through both in-house development and collaborations. 
  </p>
  <p>
    In July 2021, the company entered into a strategic partnership with SK Chemicals who will assist the company in advancing its drug development capacity. The partnership resulted in an undisclosed investment by SK Capital which will be directed toward the clinical development of Standigm’s AI-driven drug candidate for non-alcoholic steatohepatitis (NASH), which is expected to enter the clinical stage in 2022. A Synthesis Research Center was established in SK Chemicals’ headquarters based in Seongnam, South Korea, in August 2021. 
  </p>
  <p>
    The company is located in Seoul (South Korea) and opened a new office in Cambridge (UK) in August 2021 to cater to its expanding European market. 
  </p>
  <p>
    The company is planning to go public on the Korea Exchange (KRX) in the latter part of 2021. In conjunction with the IPO, it raised USD 44.5 million in a pre-IPO round in March 2021. The company also secured USD 10 million from Pavilion Capital for the clinical research of the company’s AI-driven drug compounds and to expand its access to global markets in July 2021. The last funding round brought the company’s total funds raised to date to USD 71.2 million. 
  </p>
</div>


Standigm

<div>
  <p>
    Based in the UK, Healx is a biotechnology startup focused on repurposing drugs for rare diseases using its artificial intelligence (AI) platform. Its AI platform uses natural language processing (NLP) to extract disease knowledge from published and proprietary data. Healx claims it can predict new treatments in three months and advance the drug to the clinical stage in 24 months. The company has also been working with various patient groups to collect data to be used for its AI software.
  </p>
  <p>
    The company has 18 active projects, two of which are about to enter Phase 1 or 2 of clinical trials. Its pipeline consists of drug candidates targeting rare neurological diseases, rare oncology diseases, and rare metabolic diseases. It also claims its mission is to progress 100 rare disease therapies to the clinic by 2025. Healx has partnerships with the German pharmaceutical company Boehringer Ingelheim, the Children’s Tumor Foundation (CTF), and the Foundation for Angelman Syndrome Therapeutics. In August 2021, it partnered with the Japanese pharmaceutical company Ono Therapeutics to jointly identify new disease indications with high unmet needs.
  </p>
  <p>
    Founded in 2014, the company has raised USD 67.9 million—much of which came through a USD 56 million Series B funding round in October 2019.
  </p>
</div>


Healx

<div>
  <p>
    Celsius Therapeutics is a biotechnology startup that aims to gain insights from single-cell sequencing analysis with the use of computational algorithms to find precision medicines for cancer and autoimmune diseases. Its platform collects new and archival samples around the world, prepares standardized scalable samples using artificial intelligence (AI), and analyzes thousands of samples using machine learning techniques to generate insights. The company aims to become a fully integrated drug discovery and development player, while also working with other biopharma companies.
  </p>
  <p>
    In July 2019, Celsius collaborated with Janssen Biotech to identify biomarkers that predict patient response for Janssen’s study. Celsius will receive undisclosed payments along with potential milestones based on the use of biomarkers. It will also retain the clinical level data (including insights on single-cell genomics) which can feed into its platform. The company has two programs in its pipeline focused on oncology and autoimmune diseases. The status has not been disclosed. It received USD 65 million in Series A financing as of May 2018. The company expanded its staff to 40 as of September 2019, up from 15 when it started, and aimed to expand further to 50 by the end of 2019 (current status unknown).
  </p>
</div>


Celsius Therapeutics

<div>
  <p>
    Genesis Therapeutics is an artificial intelligence (AI)-powered biotechnology company engaged in discovering and developing drugs both internally and through partnerships. Genesis uses its proprietary molecular generation engine, PotentialNet, to generate drug molecules and predict molecular properties. Its AI platform expands on the initial discoveries to uncover novel therapeutic targets that are previously considered undruggable. 
    
    In December 2020, Genesis Therapeutics raised USD 52 million in Series A funding. It aims to use the proceeds to 1) expand the team and hire AI researchers and software engineers, 2) further innovation in AI technologies, and 3) advance the drug discovery pipeline. 
  </p>
</div>


Genesis Therapeutics

<div>
  <p>
    Drug Farm is an artificial intelligence (AI) biotechnology company engaged in developing immune-modulating therapies that regulates patients' innate immunity. These therapies are targeted at hepatitis B virus (HBV), cancer, and autoimmune diseases. The company uses its drug discovery platform, IDInVivo which combines genetics and AI to assess gene targets and identify novel immunity targets. Its technology uses piggyBac transposon mutagenesis to create genetic mutations in mice, which are then analyzed to study drug targets linked to host immunity. 
  </p>
  <p>
    Founded in 2015, China and US-based Drug Farm raised USD 56 million in February 2021. The company intends to use the proceeds to advance Drug Farm’s leading drug DF-006, targeted at hepatitis B virus (HBV) infections and other liver diseases, to the clinical trial stage.
  </p>
</div>


Drug Farm

<div>
  <p>
    Engine Biosciences, based in Singapore and Silicon Valley, is a biotechnology company operating its proprietary platform, NetMAPPR, that combines artificial intelligence (AI) and cellular reprogramming to discover and develop treatments for diseases such as cancer, neurodegenerative diseases, autoimmune disorders, and skin disorders. The platform incorporates CombiGEM, the company’s patented combinatorial genetics system.
  </p>
  <p>
    Founded in 2014, NetMAPPR is being used in areas such as drug repositioning, drug discovery, and precision medicine. Engine Biosciences develops programs for various diseases both internally and via partnerships. It has collaborated with an undisclosed Fortune 500 company and leading institutions. Following a seed funding round in 2018 raising USD 10 million, the company raised USD 43 million in a Series A funding round in May 2021, bringing its total funds raised to date to USD 53 million.
  </p>
</div>


Engine Biosciences

<div>
  <p>
    Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and artificial intelligence (AI) to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), and Frontotemporal Dementia (FTD). It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
  </p>
  <p>
    Founded in 2015, Verge has six drug candidates in its pipeline with one nearing the clinical stage. Other drug candidates are at various stages of drug discovery. It has built partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine), several educational institutes, foundations (such as Target ALS, Answer ALS) and three undisclosed pharma companies. Verge raised USD 32 million in Series A funding during July 2018. The company intended to use this funding to advance its most promising candidates to the clinical stage and expand its proprietary datasets. 
  </p>
  <p>
    In July 2021, the company entered into a 3-year collaboration with Eli Lilly, to research and develop novel therapies, apart from what the company already develops, to treat ALS. Verge will identify novel targets for ALS of which 4 will be chosen by Eli Lilly for further development. It has already received USD 25 million upfront and will receive an additional USD 694 million upon achieving certain development milestones. 
  </p>
</div>


Verge Genomics

<div>
  <p>
    Based in the UK, Lab Genius is a biotechnology company that uses a combination of artificial intelligence (AI), robotic automation, and synthetic biology to develop protein therapeutics. The company’s smart robotic platform, EVA, is capable of designing, conducting, and learning from its own experiments. Lab Genius uses its platform to discover and characterize new molecules, it then partners with pharma companies to take them to market. The company is currently focusing on identifying and developing candidates for protein-based treatments for Inflammatory Bowel Disease (IBD) in partnership with Tillotts Pharma AG.
  </p>
</div>


LabGenius

<div>
  <p>
    Reverie Labs has developed a proprietary computational platform that leverages machine learning and physics-based modeling to predict important molecular properties for drug discovery and optimization. The company’s lead program is focused on targeting kinase inhibitors to treat oncology, which is currently advancing towards clinical trials. It has also entered into a multi-target partnership agreement with the pharma giant Roche to advance kinase drug discovery programs.
  </p>
  <p>
    Founded in 2017, Reverie Labs is based in Massachusetts. The company raised USD 25 million in a Series A round in February 2021. The company intends to use the proceeds to advance the company’s in-house drug discovery programs to the clinical stage, develop its computational discovery platform, and recruit more scientists and engineers.
  </p>
</div>


Reverie Labs

<div>
  <p>
    Founded in 2019, PharmCADD is a South Korean drug discovery company that uses its Pharmulator platform to generate novel drugs. The platform incorporates deep learning, molecular dimension simulation, quantum computation, and network theory. The company claims that Pharmulator can generate potent but less toxic synthetic small molecules. 
  </p>
  <p>
    The company has four products in its pipeline: an anti-cancer drug, non-vitamin K antagonist oral anticoagulants (NOAC), drugs to treat Alzheimer’s, and a COVID-19 mRNA vaccine. The company claims that its mRNA vaccine has the same efficacy as Moderna through pre-clinical trials. Its other drug candidates are in the discovery stage. 
  </p>
  <p>
    PharmCADD currently employs 50 people of which 34 members belong to R&D. In its latest funding round in April 2021, the company raised USD 16 million in Series B financing. The funds will be used for geographical expansion to India and the US, the development of its Pharmulator platform, and preclinical studies of existing drug candidates.
  </p>
</div>


PharmCADD

<div>
  <p>
    AI Therapeutics (formerly LAM Therapeutics) is a biotechnology company that has developed an artificial intelligence (AI) drug development platform to find therapeutics. Its AI and deep learning platform, Guardian Angel, use public and proprietary data on drugs and diseases to find new drug candidates.
  </p>
  <p>
    AI Therapeutics has advanced four drugs into clinical trials targeting a rare lung disease, a rare neurological disease, cancer in the lymphatic system, acute myeloid leukemia (a type of blood cancer), and facial angiofibroma. Its platform identified that out of these, one drug candidate can also be used for Covid-19, which is currently at the clinical trial Phase II stage. The company is seeking collaboration partners to commercialize these drugs. AI Therapeutics, a part of 4Catalyzer (a startup accelerator), closed USD 58 million in Series C financing in March 2017.
  </p>
</div>


AI Therapeutics

AI Drug Discovery & Development

<div>
  <p>
    Schrödinger operates a physics-based software platform to provide computational services for drug discovery. The company was formed in 1990, long before the artificial intelligence (AI) disruption in drug discovery, and has been involved in the business of providing computational software solutions to pharma and biotech companies. Its platform has been built on the foundation of physics, combined with the rapid data processing and scaling advantages of machine learning. Schrödinger claims physics-based simulation is capable of predicting the binding affinity of a drug molecule with a high degree of accuracy, which can, in turn, lead to the accelerated discovery of new efficacious therapies. The company’s business can be categorized into two segments: software and drug discovery. The software segment focuses on selling its software to support drug discovery. Its software solutions are for all key stages of drug discovery (target identification/validation, lead generation, and lead optimization). The drug discovery segment is focused on discovering and developing drugs through collaborations or internally (since 2018).
  </p>
  <p>
    The company has collaborations with various pharma companies including Sanofi, Ono Pharmaceutical, and Takeda Pharmaceutical. Through the software segment, the company has supported the development of two drugs which are approved by the US Food and Drug Administration (FDA) with many in the clinical stage. Schrödinger has five wholly-owned programs that are at the discovery stage. The company also has equity investments in Nimbus Therapeutics and Morphic Therapeutic. It filed for an IPO in February 2020, raising USD 202 million. Schrödinger recorded revenue of USD 66.6 million in 2019, rising 28.4% YoY. This can be attributed to the growth in the company’s software segment where the customer base grew to 1,266 from 1,150 during the same period, as well as an increase in the number of collaboration milestones for the drug discovery segment. The company recorded a net loss of USD 28.4 million in 2019, increasing 10.4% YoY.
  </p>
</div>


Schrödinger

<div>
  <p>
    Based in Hong Kong, Insilico Medicine is an artificial intelligence (AI) drug discovery company focused on three areas of drug discovery and development: disease target identification, generation of synthetic biology and novel molecules data, and predicting clinical trial outcomes. The company's key focus area is anti-aging interventions, however, there is also a therapeutic focus on areas such as oncology, dermatology, metabolic diseases, neuroscience, and rare diseases. It is the leader in aging research with nearly a quarter of the company’s research and development (R&D) budget committed toward aging diseases. The company collaborates with pharma companies and also has its own pipeline of small molecules targeting many disease areas which the company aims to license to pharma players later. The company also provides several customer-facing tools for registered users, such as Young.AI and Aging.AI, which help to measure multiple predictors and biomarkers of aging.
  </p>
  <p>
    In a landmark achievement, Insilico announced in September 2019 that by using its AI platform, it was able to discover a new lead compound for idiopathic pulmonary fibrosis (IPF) in just 46 days compared to the two-to-three-year timespan required for traditional drug discoveries. The company also completed the entire preclinical stage, from the earliest stages of identifying potential targets, in a record time of 18 months. This breakthrough, announced in February 2021, was a catalyst for the company’s latest Series C funding round in June 2021 in which it raised USD 255 million, bringing its total funds raised to USD 310 million. The funds will be mainly used to initiate human trials on the lead candidate, to be commenced by the end of 2021. 
  </p>
  <p>
    Insilico’s CEO remains bullish on the business potential of the Asian region, especially China. Currently, the company is actively pursuing further collaborations with Chinese pharmaceutical companies. 
  </p>
</div>


Recursion Pharmaceuticals

<div>
  <p>
    Relay Therapeutics is a biotechnology company engaged in developing precision medicine evaluating the movement of proteins (protein motion) with the help of artificial intelligence (AI) and a supercomputer-powered platform. The company’s initial focus is on precision oncology, but it believes its platform will have applications in other areas of precision medicine such as genetic diseases. Its platform, Dynamo, uses a custom-built supercomputer engineered by David E. Shaw, one of the company’s co-founders. Dynamo can be mainly used in target identification, lead generation, and lead optimization.
  </p>
  <p>
    The company has three drug candidates in its wholly-owned pipeline: 1) RLY-1971, which acts as a protein inhibitor in solid tumors, and is at the Phase I stage of clinical trials; 2) RLY-4008, which is designed to inhibit fibroblast growth factor receptor 2. The company intends to bring this to clinical trials by the end of 2020; and 3) RLY-PI3K1047, which targets cancer-associated variants of phosphoinositide 3-kinase alpha and is currently at the preclinical stage. In addition to these, Relay also has five programs at the discovery stage across precision oncology and genetic diseases. The company went public in July 2020, raising USD 425 million, one of biotech’s largest IPOs of 2020. The company has not generated any revenue from product sales or any other sources and does not expect to generate revenue from product sales in the near future. It recorded net losses of USD 75.3 million in 2019, increasing 54.3% from 2018.
  </p>
</div>


Relay Therapeutics

<div>
  <p>
    California-based Erasca is a biotechnology company that develops oncology therapeutics. The company’s name is derived from its aim to “erase cancer” and it focuses on developing therapies that go after RAS - the most frequently mutated oncogene in human cancer, and the MAPK pathway, which is one of the most frequently altered signaling pathways in cancer.
  </p>
  <p>
    It operates an artificial intelligence (AI) drug discovery platform, Oncology Pattern Recognition Algorithm (OPRA), which is capable of analyzing large-scale data sets to find therapeutics for cancer.
  </p>
  <p>
    Founded in 2018, the company’s pipeline of in-house precision therapies for undisclosed cancer targets includes 11 modality-agnostic programs targeting the RAS/MAPK pathway. The company's lead programs are EROS-007 (Phase 2 clinical trial stage) and ERAS-601 (Phase 1 clinical trial stage). The company also has two other small molecule inhibitor discovery programs namely ERAS-9 and ERAS-11, that do not target the RAS/MAPK pathway. The company expects four of its product candidates to be ready for initial clinical trials within the next six quarters.
  </p>
  <p>
    The company also seeks to enter into a partnership with other pharma companies to expand its pipeline. Erasca claims it does not limit its experiments to one form of drug or a single approach to treating cancer. 
  </p>
  <p>
    Erasca went public on the Nasdaq Global Select Market under the ticker symbol “ERAS” in July 2021, raising gross proceeds of up to USD 345 million to fund operations for the next two years including the clinical development of its oncology programs and advancement of its in-house drug discovery pipeline.
  </p>
</div>


Erasca

<div>
  <p>
    Gritstone Oncology is a biotechnology company engaged in developing tumor-specific immunotherapies for various types of cancer. Its proprietary artificial intelligence (AI) platform, Gritstone Edge, is designed to predict tumor-specific neoantigens from a routine tumor biopsy. Based on this, the company develops immunotherapies that can drive the patient’s immune system to attack and destroy tumors. The company claims its platform has shown a nine-fold improvement in accuracy for predicting tumors in comparison to publicly available approaches. It has two product candidates: personalized neoantigen-based immunotherapy for patients with common solid tumors, including non-small-cell lung cancer, gastroesophageal cancer, bladder cancer as well as another immunotherapy that uses a fixed set of neoantigens that are shared across a subset of cancer patients (unlike personalized therapy) targeted at common solid tumors. Both of these are at Phase I of the clinical trial stage. It also has two other programs that are at the discovery stage.
  </p>
  <p>
    Gritstone entered into a strategic collaboration with Bluebird Bio in 2018 to develop novel cancer cell therapies. Bluebird will use Gritstone’s AI platform to research, develop, and commercialize cell therapies for cancer. In return, Gritstone could earn more than USD 30 million in upfront and additional payments. Gritstone is also eligible for milestone payments for all therapies and tiered royalties on certain therapies. The company filed for an IPO in September 2018, raising USD 100 million. The company has not generated any revenue from product sales and states that it does not expect to generate revenue from product sales for the foreseeable future. For 2019, it reported USD 4.4 million in revenue from collaborations, nearly four times higher than revenue recorded in 2018 (USD 1.2 million). The growth is attributed to the partnership it entered with Bluebird Bio. Gritstone reported net losses of USD 94.3 million, increasing 45.8% YoY which can be primarily attributed to the growth in research and development (R&D) (50.7% YoY). Its future strategy is to advance its two key product candidates to the Phase II clinical stage before the end of 2021.
  </p>
</div>


Gritstone Oncology

<div>
  <p>
    Based in the UK, e-therapeutics operates network-driven drug discovery platforms that leverage the power of big data and artificial intelligence (AI). Network-based platforms are founded on the practical application of network biology which considers the underlying molecules such as proteins and nucleic acids. The company believes this unique approach is an efficient way of identifying and developing effective therapies. It has two platforms; the first is Network-Driven-Drug-Discovery, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct millions of experiments, and the second is Genome-Associated Interaction Networks (GAINs), which is capable of identifying disease variants at the genome level (or DNA variants) to develop therapies.
  </p>
  <p>
    E-therapeutics has partnered with Novo Nordisk, the Danish multinational pharma company, since 2018 where the latter will use the GAINs platform to analyze data from diabetes patients. It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration. In 2007, the company was listed on the Alternative Investment Market, London Stock Exchange’s public market for small and medium-sized growth companies. E-therapeutics’s recognized revenue of GBP 500,000 (approximately USD 654,000) after year-end in January of 2020, growing more than 10-fold from the previous year. Revenue growth mostly comes from the commercial deal it signed with Novo Nordisk. As a result, operating losses nearly halved to GBP 2.9 million (around USD 3.79 million) for the year, ending in January of 2020.
  </p>
</div>


eTherapeutics

<div>
  <p>
    Lantern Pharma is a biotechnology company combining artificial intelligence (AI), genomics, and machine learning to deliver precision oncology therapies. The company’s proprietary platform RADR is used for drug discovery, biomarker discovery, drug repurposing, and the development of precision therapeutics. It claims the platform has more than 4.6 billion data points and uses big analytics, combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, and phenotypic trials and publications, as well as mechanistic pathway data.
  </p>
  <p>
    Founded in 2013, Lantern Pharma currently has five candidates in the pipeline. Candidates for prostate cancer and non-small lung cancer are in the clinical trial stage (Phase II and Phase I, respectively). Candidates for solid tumors and glioblastoma are in the preclinical stage, and another drug candidate for solid tumors is in the early stages. The company launched its IPO in June 2020, raising USD 26.3 million in the process; however, it has not generated any revenue yet. It recorded a net loss of USD 2.4 million for the first quarter ended March 2021. Additionally, Lantern Pharma collaborated with Actuate Therapeutics in May 2021 to accelerate the latter’s drug candidate for cancer and fibrotic disease.
  </p>
</div>


Lantern Pharma

<div>
  <p>
    Based in Denmark, Evaxion Biotech is a biotechnology company specialized in the discovery and development of immunotherapies against cancer and other diseases using its two internally developed artificial intelligence (AI)-based platforms that leverage the power of neural networks and big data. Its PIONEER platform is focused on developing personalized immunotherapies while the EDEN platform identifies vaccine antigens to trigger protective immune responses against infectious diseases. Its RAVEN platform designs and develops vaccines for emerging and mutating viral diseases.
  </p>
  <p>
    Founded in 2008, the company has three personalized patient-specific cancer immunotherapies in the pipeline developed by the PIONEER platform— two of which are in Phase 2a clinical trials with another in the preclinical stage. The company also has one vaccine against bacterial diseases developed by the EDEN platform in preclinical stages.  
  </p>
  <p>
    The company went public on the Nasdaq under the ticker symbol “EVAX” in February 2021, raising USD 30 million. 
  </p>
</div>


Evaxion Biotech

<div>
  <p>
    Headquartered in Colorado, Mydecine Innovations Group (formerly called NewLeaf Brands) is a biopharmaceutical and life sciences company focusing on the research and development of psychedelic and natural substances for medicinal use through its subsidiary Mydecine Health Sciences—which aims to discover new functional and psychedelic compounds to treat mental disorders. 
  </p>
  <p>
    In June 2021, Mydecine launched an artificial intelligence (AI) drug discovery program in collaboration with the University of Alberta to leverage AI and machine learning technologies to screen hundreds of thousands of new molecules without the need to produce them physically, thus expediting the drug discovery and development process.
  </p>
  <p>
    Mydecine is traded on the Canadian Securities Exchange (CSE). For the year ended December 2020, the company recorded revenue of CAD 58,490 (USD 47,706) and reported a loss of CAD 26.9 million (USD 21.9 million), compared to recorded revenue of CAD 125,572 (USD 102,419) and losses of CAD 2.4 million (USD 2.0 million) for the corresponding period in 2019.
  </p>
</div>


Mydecine Innovations Group

<div>
  <p>
    UK-based Exscientia is a full-stack AI drug discovery firm with discovery-to-clinical capabilities. The company uses its proprietary Centaur Chemist technology to assess disease targets specified by its clients and to prioritize potential disease targets for its own pipeline.
  </p>
  <p>
    It follows the Bispecific (dual-target) novel and highly complex approach that attempts to identify two simultaneous and distinct targets that perfectly bind with a drug compound, as opposed to identifying a single target. This can save considerable costs as a single drug can deliver the same efficacy as two different drugs. The company’s AI algorithms are disease agnostic, which means the platform can be applied to any disease targets across a wider range of disease types, such as oncology, cardiovascular, and rare diseases. The company also claims to be the first to apply AI to small molecule drug discovery and design.
  </p>
  <p>
    In a landmark development, Exscientia advanced the first fully AI-developed drug into human clinical trials in partnership with Sumitomo Dainippon Pharma (SDP) in January 2020. The drug discovery and preclinical research were completed in less than 12 months, a fraction of the five-year average for the same process using conventional research techniques. 
  </p>
  <p>
    The company has formed nine partnership projects since its inception in 2012 that include several large pharmaceutical players such as Sanofi, GSK, Roche, Bayer, Celgene, Sumitomo Dainippon Pharma and the latest one with GT Apeiron Therapeutics in July 2021. The company has also received two grants from the Bill & Melinda Gates Foundation (BMGF): USD 4.2 million in December 2020 for malaria tuberculosis and non-hormonal contraception treatments, and USD 1.5 million in July 2021 to quickly develop therapies for Covid-19. It also entered into a USD 70-million partnership with BMGF in September 2021 to develop therapies for viral diseases. In addition, it also has several co-development projects with Evotec, Apeiron and Rallibio. 
  </p>
  <p>
    Exscientia filed for an IPO in September 2021, to raise USD 100 million on Nasdaq. Upon necessary approvals, it would trade under the ticker symbol “EXAI”. In its last private Series D funding round in April 2021, the company raised USD 225 million, which brought its total raised funds to USD 374 million (excluding a discretionary equity of USD 300 million from SoftBank). 
  </p>
</div>


Exscientia

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

<div>
  <p>
    Lodo Therapeutics is a biotechnology company engaged in developing novel therapeutics using an artificial intelligence (AI)-powered drug discovery platform. Its platform uses in-silico methods (computer simulations) to identify promising drug-like molecules at the DNA level. Instead of culturing the organism, its platform identifies genetically encoded small molecules from microbial sources, such as uncultured soil bacteria, human commensal bacteria, and pathogenic bacteria.
  </p>
  <p>
    The company has a partnership with the biotechnology company Genentech, where the latter will use the company’s proprietary platforms to identify molecules with therapeutic potential against multiple disease targets. Lodo Therapeutics is eligible for up to USD 969 million in upfront and milestone payments, along with tiered royalties on sales of certain products resulting from the collaboration. The company achieved a preclinical milestone in this collaboration in April 2020.
  </p>
</div>


Lodo Therapeutics

<div>
  <p>
    Arbor Biotechnologies is a biotechnology startup that operates a biodiscovery platform to discover novel Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene-editing enzyme that helps to alter RNA to treat genetic diseases. Arbor has a partnership with Vertex, a leading pharma company to accelerate gene-editing therapies.
  </p>
</div>


Arbor Biotechnologies

<div>
  <p>
    Co-founded by Atomwise and Velocity Pharmaceutical Development, X-37 is a biotechnology company focused on drug discovery and development. The company utilizes Atomwise’s platform to discover novel drug candidates. Once discovered, X-37 leverages its team of industry professionals to advance the drugs from initial screening to preclinical testing. As of September 2020, the company had five potential drugs under development which are currently undergoing testing and screening. These drugs relate to autoimmune diseases, cancer, and anticoagulation with human testing expected to begin by 2022.
  </p>
</div>


X-37

<div>
  <p>
    An artificial intelligence (AI)-powered drug discovery and development company, twoXAR has partnerships with Santen Pharmaceuticals from Japan, Adynxx, and Firecebiotech, among others. The company generates revenue through a combination of upfront payments, milestone, and royalty payments. As of September 2020, the company had over 18 different disease programs in the pipeline, including cancer, chronic kidney diseases, nonalcoholic steatohepatitis, etc. with 10 candidates at the preclinical stage.
  </p>
</div>


twoXAR

<div>
  <p>
    Phenomic AI’s drug discovery platform uses machine learning tools for processing imaging and RNA sequencing data to study the complex interactions in multi-cell systems. Its technology is targeted at tumor stroma (includes connective tissue, blood vessels, and inflammatory cells) which is considered a major barrier in treating solid tumors. The company develops drug targets for cancer and fibrosis which it aims to advance internally or via partnerships with other pharma companies.
  </p>
</div>


Phenomic AI

<div>
  <p>
    The company uses an artificial intelligence (AI)-driven platform to determine and test therapies for cancerous cells based on patient-derived 3D organoids, enabling the development of personalized cancer treatments for patients. The company achieves this through its proprietary diagnostics platform PARIS. This platform is used by leading oncologists across the US. The company also entered into a joint venture with Atomwise to accelerate oncology drug discovery by leveraging combined expertise. As of September 2020, the company is working on developing four candidates (two in partnership with Atomwise), two of which are undergoing organoid testing while the other two are in the target validation stage.
  </p>
</div>


SEngine Precision Medicine

<div>
  <p>
    Fountain Therapeutics operates an artificial intelligence (AI)-powered platform that seeks to develop therapeutics aimed at reversing cellular aging and preventing age-related diseases. The platform features an AI-based drug screening system and animal models for disease modeling and preclinical testing.
  </p>
</div>


Fountain Therapeutics

<div>
  <p>
    Turbine operates Simulated Cell, a proprietary simulation-based drug discovery platform that generates novel oncology therapies. The platform models human cell behavior to run a vast number of cloud-based experiments. Turbine’s simulations also measure the changes in tumor cells across the entire research and development (R&D) process.
  </p>
  <p>
    The Hungarian company has collaborated with pharmaceutical companies including Bayer to support their oncology pipeline. In January 2021, the company raised EUR 5.7 million (USD 6.9 million) in a pre-Series A round, bringing its total funding to EUR 9 million (approximately USD 11 million). Turbine expects to use the proceeds to expand its simulation platform’s focus on unmet needs in oncology and advance its novel target candidates against PARP resistance (poly ADP ribose polymerase), which affects the majority of cancer patients who undergo PARP inhibition therapies, to the clinical stage. 
  </p>
</div>


Turbine

<div>
  <p>
    Endogena Therapeutics discovers and develops endogenous regenerative therapeutics for common degenerative diseases. The company’s most advanced program, retinitis pigmentosa, targets degenerative eye diseases. Its drug pipeline also includes candidates for dry macular degeneration, idiopathic pulmonary fibrosis, haematopoiesis, and other eye disorders.
  </p>
  <p>
    Endogena was founded in 2016 and is based in California. The company raised USD 8 million in the first round of Series A financing in January 2021. The company aims to use the proceeds to establish clinical proof of concept for its lead drug program, retinitis pigmentosa. Endogena also intends to receive an investigational new drug application (IND) for its age-related macular degeneration program and add new programs using its AI drug discovery platform. 
  </p>
</div>


Endogena Therapeutics

<div>
  <p>
    Unnatural Products uses artificial intelligence (AI) to create new drugs for traditionally undruggable targets by engineering macrocycles, which are molecules found in nature. The company plans to build a pipeline of compounds with a focus on identifying cancer treatments initially.
  </p>
</div>


Unnatural Products

<div>
  <p>
    Envisagenics provides the SpliceCore discovery platform that applies artificial intelligence (AI) and RNA sequencing to identify RNA splicing errors, which can then be used for target discovery, biomarker discovery, and identification/testing of potential therapeutics (both internally and in partnership with other institutions). As of April 2020, the company is preclinically developing a candidate for the treatment of Triple Negative Breast Cancer (TNBC). In April 2020, the company entered into a research partnership with Johnson & Johnson to build predictive models for lung cancer progression and risk.
  </p>
</div>


Envisagenics

<div>
  <p>
    UK-based Kuano is a drug discovery company that leverages the power of  AI, quantum physics, and medicinal chemistry to generate enhanced enzyme inhibitors which the company says are required for the creation of superior drugs. Its discovery platform performs enzyme modeling through quantum mechanical simulations to generate enzyme inhibitors that have strong binding at the quantum transition state, are highly selective, and can withstand mutations that cause loss of enzyme function. 
  </p>
  <p>
    This approach is based on simulating quantum transition states in silico and does not rely on structure based drug discovery (SBDD) which uses ligand binding data. The company says SBDD is a time consuming and costly process and is based on an imperfect model of ligand-enzyme interactions.
  </p>
  <p>
    The company’s platform is used for the company’s own therapeutics pipeline and with collaborative programs with academic partners including Alzheimer’s Research UK and the University College London Drug Discovery Institute.
  </p>
  <p>
    In June 2021, the company was awarded a grant by the UK Government under the “InnovateUK - Business-led innovation in response to global disruption” initiative to build a combined AI and modelling service for rapid response drug design to tackle the Covid-19 pandemic. The company is also a part of the Covid-19 High Performance Computing Consortium, working with Amazon Web Services (AWS) on accelerating the development of therapeutics to treat the virus. 
  </p>
  <p>
    Founded in 2020, the company raised GBP 1 million (USD 1.4 million) in a seed funding round in July 2021. The proceeds will be directed towards advancing its AI platform and growing its drug portfolio and technology team. 
  </p>
</div>


Kuano

<div>
  <p>
    Berg is an artificial intelligence (AI)-powered biotechnology company that uses its platform to map diseases and identify biomarkers, which helps accelerate the development of treatments. The company has its own pipeline and works with several pharma, healthcare, and academic institutions. As of September 2020, Berg had a strong pipeline of candidates for the treatment of solid tumors in Phase I and Phase II clinical trials, along with a candidate for treatment for chemotherapy-induced hair loss which is in Phase I clinical trials. The company also has several other candidates for oncology and neurology in varying levels of progress in the drug discovery stage.
  </p>
</div>


Berg

<div>
  <p>
    Massachusetts-based biotechnology company Shepherd Therapeutics operates Delve, an AI-enabled drug positioning and development platform. The platform combines machine learning, bioinformatics, and traditional research to develop new drugs for rare cancers. It stores health-related data from public and internal data sources to identify complex and interconnected mechanisms responsible for drug response and resistance. 
  </p>
  <p>
    Founded in 2015, the company is currently developing agents that show activity against multiple rare cancers. It has internal programs which are at the early stages of drug discovery and is also collaborates with pharma companies to advance research on rare cancers.
  </p>
</div>


Shepherd Therapeutics

<div>
  <p>
    Genuity Science, restructured from the China-based WuXi NextCODE, is engaged in providing genomic research and insights to pharma and biotech companies for drug discovery and development. Its solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its artificial intelligence (AI)-powered platform to manage, process, and analyze genomic data. Its partnerships are focused on developing therapies for difficult-to-treat common diseases such as nonalcoholic steatohepatitis (NASH), heart failure, and multiple sclerosis.
  </p>
  <p>
    Following the restructuring, which was announced in 2019, the company has cut off its ties to WuXi NextCODE’s Shanghai operations. The new company will be based in the US, with operations in Iceland and Ireland (formerly operated as Genomics Medicine Ireland). In August 2020, it collaborated with Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center to discover drug targets and biomarkers. The company closed USD 200 million in Series C funding in November 2018, raising its total funding to USD 455 million. The investor base remains the same despite the restructuring, consisting of Sequoia Capital, Temasek, etc.
  </p>
</div>


Genuity Science

<div>
  <p>
    Headquartered in Singapore and the UK, Patsnap is an intellectual property analytics company. It operates a software platform that uses artificial intelligence (AI) technology to combine millions of data points from patents, licensing, litigation, and other sources to provide intelligence that helps companies streamline research and development (R&D) departments. Its main solutions include IP Intelligence (to track patent filings in the market, including competitors), R&D intelligence (tracking all sorts of R&D-related data points such as market reports, government grants, and clinical trials to provide R&D insights), Life Science (sequence-searching platform), and Chemical (validate chemical development projects by analyzing big data). The life science-focused solution, PatSnap Bio, allows pharma companies to search for protein, DNA, and RNA sequences within patent and non-patent sources in order to improve their R&D process.
  </p>
  <p>
    The company has more than 8,000 customers worldwide across various industries with offices in nine locations. It has partnered with Chemical Abstracts Service, a division of the American Chemical Society, to receive wide coverage of manually curated patents and non-patent sequences from proprietary sources.
  </p>
</div>


PatSnap

<div>
  <p>
    DNAnexus operates a cloud-based data analysis platform to provide genomic research. In addition to pharmaceutical and biotech companies, its platform is being used by diagnostic test providers, sequencing service providers, academic labs, and genome centers. DNAnexus has three products: 1) Apollo, to support data science exploration, analysis, and discovery, 2) Titan, for sequencing data analysis and 3) Portals, a collaborative space for organizations.
  </p>
  <p>
    The company offers its platform to more than 100 enterprise customers including eight large clinical diagnostic companies and seven big pharma companies across various countries. It has also attracted the interest of Google Ventures, the venture capital arm of Alphabet Inc. In 2015, they partnered with the US Food and Drug Administration (FDA) to develop a platform that tests the accuracy of diagnostic genetic tests. In 2017, they partnered with AstraZeneca to analyze over two million genomes through 2027. It is also working with Regeneron Genetics Center, which uses DNAnexus's interface to query data from the UK Biobank, an academic-run database of genomic and clinical data. DNAnexus raised Series G funding of USD 100 million in June 2020, its latest funding round, which will be used to fund the platform, its corresponding studies, and more specifically, research related to Covid-19.
  </p>
</div>


DNAnexus

<div>
  <p>
    New Jersey-based Axtria develops cloud platforms and AI-enabled data analytics to help life sciences companies expedite the process of bringing therapeutics to the market. Axtria has four AI-based SaaS cloud platforms: Axtria DataMAx, Axtria InsightsMAx, Axtria SalesIQ and Axtria CustomerIQ. The company's DataMAx and InsightsMAx focus on data management and analytics for drug discovery. The company also provides information management, consulting, and managed services.  
  </p>
  <p>
    The company’s client base includes more than 100 life sciences companies ranging from pharma to biotech, medical devices and diagnostics, consumer health, animal health, and payers and providers. Axtria also maintains partnerships with large tech firms including Amazon Web Services (AWS), Salesforce, Microsoft, and Reltio. 
  </p>
  <p>
    Founded in 2010, the company received a growth investment of USD 150 million from Bain Capital in May 2021 which brought its total capital raised up to USD 206.2 million.
  </p>
</div>


Axtria

<div>
  <p>
    Nference operates a biomedical knowledge synthesis platform that captures and analyzes health data, including unstructured information to help researchers in drug discovery. Its platform is powered by artificial intelligence (AI) and uses neural networks (shallow and deep learning models) for the automatic extraction of insights from clinical notes, scientific literature, pathology images, ECG waveforms, and genomic sequences.
  </p>
  <p>
    The company entered into a partnership with Mayo Clinic in 2017 to synthesize and analyze genomic and clinical data from Mayo Clinic and public databases. Nference was Mayo Clinic’s first clinical data analytics platform partner. In 2019, Janssen Research & Development partnered with Nference to discover and develop new therapeutics. The company raised USD 60 million in Series C financing as of December 2020 which the company will direct toward the development of its platform.
  </p>
</div>


nference

<div>
  <p>
    Owkin has created a research platform that connects data scientists, clinicians, academic researchers, and pharma companies to enable collaborative research without centralizing data (patient data will be retained within a hospital’s local infrastructure). This medical research ecosystem consists of four tools: Owkin Loop (the network), Owkin Connect (the technology infrastructure), Owkin Studio (the artificial intelligence software tool) and Owkin Lab (the expertise). This method is touted as a way to maintain privacy and security while leveraging data-driven insights. To ensure accuracy, the artificial intelligence (AI) model is trained on the data which will monitor for variance.
  </p>
  <p>
    Owkin is currently coordinating a drug discovery project between 10 pharmaceutical companies, including Bayer and Novartis, and another project between four medical centers. Owkin’s technology allows free access to academic researchers while having paid agreements with pharma companies. In July 2020, the company raised USD 18 million in Series A funding, two months after raising USD 25 million. Google Ventures (Alphabet’s venture capital arm) is an early investor in Owkin.
  </p>
</div>


Owkin

<div>
  <p>
    Based in China, Zilliz is an artificial intelligence (AI)-powered unstructured data analytics startup which also operates in the US. The company released its flagship open-source unstructured data service, Milvus, in 2019. Milvus can analyze large unstructured data in the form of images, videos, chemical structures, and gene sequences. It is being used by more than 400 enterprises for various applications, including new drug development and gene analysis. 
  </p>
</div>


Zilliz

<div>
  <p>
    Flywheel operates a cloud-based medical research data management and collaboration platform which captures and curates clinical data from multiple sources such as imaging, electronic health records (EHRs), digital pathology and omics, and enables further processing. The company’s services are targeted at companies in life sciences, clinical research, imaging research, and AI health development markets. It counts leading research institutions such as Stanford University, University of Pennsylvania, University of Michigan, and Massachusetts General Hospital, and Boston Children’s Hospital among its clientele. 
  </p>
  <p>
    Founded in 2012, Flywheel is based in Minnesota. The company last raised USD 15 million in a February 2021 Series B funding round. It aims to use the proceeds to strengthen Flywheel’s presence in life sciences and AI research, and accelerate product development with a focus on both the pharmaceutical industry as well as academia.
  </p>
</div>


Flywheel

<div>
  <p>
    Kyndi operates an artificial intelligence (AI) platform that can analyze large bodies of unstructured and long-form text. The company mainly serves customers in the pharmaceutical industry, defense, financial services, and manufacturing. In the pharma sector, its platform can be used in various stages from research and development (R&D) to marketing. The AI platform is capable of identifying keywords, custom entities, and phrases to detect trends, find answers using natural language processing, provide data context and location, and can learn industry terminologies. It can be used to search through medical literature and reports to produce insights and develop dashboards to track various information from clinical studies.
  </p>
</div>


Kyndi

<div>
  <p>
    Molecular Health is an artificial intelligence (AI) computing company that focuses on data science to enable and improve decision-making in precision medicine for healthcare companies. By capturing, integrating, and analyzing the molecular and clinical data of individual patients against globally available medical, biological, and pharmacological knowledge, it aims to bring about more precise diagnostic, therapeutic, and drug safety decisions. Its proprietary cloud-based Datatome Technology platform is designed to present actionable intelligence at the molecular level to improve diagnosis and therapy decisions by physicians and support better drug discovery, development, and trial optimization. In addition, it aims to assist healthcare organizations to improve their accuracy in predicting the likelihood of success and approval of drug candidates in clinical development.
  </p>
  <p>
    In July 2020, Molecular Health collaborated with Centogene N.V., a commercial-stage company focused on rare diseases, to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project, starting with epilepsy. The collaboration aims to apply AI and scientific computing to create a novel precision medicine environment to accelerate the development of new orphan drugs by merging real-life data with globally curated biomedical knowledge and transform biomedical research, product development, and therapy.
  </p>
</div>


Molecular Health

<div>
  <p>
    Greek-owned Intelligencia, headquartered in New York, is an AI/ML software platform that caters to pharmaceutical and biotechnology companies. The company uses proprietary and curated data with ML algorithms to quantify and ultimately reduce the risk of clinical development and speed up the drug development process. It also uses AI to predict the likelihood of clinical trial success and provides input on how to improve or other areas of research that can be targeted. 
  </p>
  <p>
    The company offers four solutions that aim to reduce risks in drug development, improve productivity and costs across preclinical and clinical development, and boost business strategies. These solutions are 1) Portfolio Optimizer - to assess the probability of technical and regulatory success (PTRS) of drug pipelines; 2) Asset Optimizer - to run predictive analytics and sensitivity analyses on hundreds of parameters to design trials; 3) Business Development and Licensing (BD&L) navigation - to identify and prioritize external assets for specific areas of interest; and 4) Breakthrough Science - to give access to a library of emerging technological and scientific data. 
  </p>
  <p>
    Founded in 2017, the company raised USD 12 million in Series A funding in August 2021 to expand its research and development (R&D) and sales teams and broadening its product offerings and customer base. 
  </p>
</div>


Intelligencia

<div>
  <p>
    InveniAI provides artificial intelligence (AI) drug discovery services to pharmaceutical companies to accelerate drug development by leveraging its AIphaMeld technology, a universal signal detection system that uses AI and machine learning technologies. 
  </p>
  <p>
    Its AlphaMeld AI platform helps identify alpha signals for targets, drugs, and healthcare products. The company caters to a range of industries, including healthcare, food and nutrition, agri-tech, aviation, chemicals, and government.
  </p>
  <p>
    The Connecticut-based firm was spun out from its parent company BioXcel LLC in 2017 to focus on AI applications for drug discovery and development. It currently has 3 AI-powered drugs in its pipeline: two new chemical entities (INVA8002 and INVA8003) and one novel combination of approved drugs (INVA8001). An investigational new drug (IND) application is expected to be submitted for INVA8001 in Q4 2021, for INVA8002 in Q2 2022, and INVA8003 in Q4 2022.
  </p>
  <p>
    The company has multiple drug development collaborations with biopharma and biotech companies and around 10 collaborative drug programs in its pipeline to treat chronic inflammatory diseases. 
  </p>
  <p>
    In July 2021, InveniAI entered into a collaboration with the Japanese pharmaceutical company Shionogi in April 2021—followed by a multi-target drug discovery collaboration with Sosei Group Corporation, a G-protein coupled receptors (GPCRs)-focused drug discovery company—to generate novel compounds for unmet conditions. 
  </p>
</div>


InveniAI

AI SaaS | Data Aggregation and Research

<div>
  <p>
    Nautilus Biotechnology is developing a single-molecule protein analysis platform to quantify human proteome. By doing so, the company intends to improve the speed and success rate of therapeutic development, particularly personalized and predictive medicine. In addition, the company claims the platform can also identify biomarkers to enable new diagnostics. 
  </p>
  <p>
    Founded in 2016, the company’s focus is on the field of proteomics with technology that incorporates the preparation of a protein array that identifies and quantifies millions of protein molecules collected from blood, tissue or cells. The platform will also decode and analyze the protein molecules and their individual properties. The company’s database of protein molecules will improve with the database growing with more proteome information. 
  </p>
  <p>
    In December 2020, Nautilus formed a collaboration with the pharma giant Roche’s subsidiary, Genentech, to utilize the company’s technology to analyze and map the various forms of a particular protein. 
  </p>
  <p>
    In July 2021, the Seattle-based company went public on Nasdaq via a special-purpose acquisition company (SPAC), under the ticker symbol “NAUT”, and raised USD 345 million.
  </p>
</div>


Nautilus Biotechnology

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

<div>
  <p>
    Based in the UK, Cambridge Cancer Genomics develops software to help oncologists detect relapse earlier, predict response to therapy, and reduce ineffective treatment regimens. It operates two platforms: OncOS and OncAI. OncOS is targeted at precision oncology by providing various datasets, while OncAI operates as a biomarker oncology discovery tool for clinical trial stratification and patient selection. In February 2020, the company partnered with Precision-Panc to offer precision medicine clinical trials to patients with pancreatic cancer.
  </p>
</div>


Cambridge Cancer Genomics

<div>
  <p>
    OccamzRazor builds complete maps of diseases to get a thorough understanding of how the disease works, identify biomarkers and develop new therapeutic targets. It achieves this by using artificial intelligence (AI) and natural research processing algorithms to read scientific reports and data. The company is currently working on Parkinson’s disease and is the first entity to map all the information about this disease. OccamzRazor has entered into partnerships with various academic institutes.
  </p>
</div>


OccamzRazor

<div>
  <p>
    Ozette is developing an immunity monitoring platform that helps scientists make decisions to improve patient care and outcomes through insights generated from single-cell data. The company was spun out of a collaboration between the Fred Hutchinson Cancer Research Center and the Allen Institute for Artificial Intelligence (AI2) in 2020.
  </p>
  <p>
    Seattle-based Ozette raised USD 6 million seed funding in February 2021. The company aims to use the proceeds to develop the company’s AI-powered immune monitoring platform, as well as hiring additional data scientists, engineers, computational biologists, and immunologists.
  </p>
</div>


Ozette

<div>
  <p>
    Boston-based Rhino Health’s platform offers AI developers access to real-world patient data curated from a diverse group of patients while maintaining patient confidentiality and privacy. The company’s Federal Learning capabilities enable hospitals and care providers to access patient data without moving or transferring ownership of datasets. 
  </p>
  <p>
    Rhino Health emerged from stealth and raised USD 5 million in seed funding during February 2021. The company has also unveiled a collaboration with NVIDIA for its federated learning platform, Rhino Health, to be used in NVIDIA Clara (an application framework for healthcare developers) to help clinicians build AI models.
  </p>
</div>


Rhino Health

<div>
  <p>
    Molecule.one is a Polish AI-based drug design and molecule synthesis startup founded in 2016. It operates a cloud-based computational chemistry platform that assists drug developers in accelerating the discovery process by leveraging AI to design synthesis pathways and create molecules.
  </p>
  <p>
    The company’s approach to converting a structure to synthesis is based on three steps: 1) draw and edit molecular structures using its Molecular Editor, 2) design synthesis and identify the success rate, 3) view results and recommendations. Molecule.one also pitched at the TechCrunch Startup Battlefield in 2019, becoming the first startup from the Central and Eastern European region to do so. 
  </p>
  <p>
    The company raised USD 4.6 million in a seed funding round in June 2021 and intends to use the funds to grow its team and open new offices in the US and Western Europe. The company has raised a total of USD 5 million.
  </p>
</div>


Molecule.one

<div>
  <p>
    PostEra is a University of Cambridge spin-out company engaged in utilizing machine learning technology to design novel molecular structures. Its approach is based on combining chemical synthesis with molecular designing. In addition to collaborating with drug developers, it also operates a chemical database, Manifold, to offer some of its synthesis technology. 
  </p>
  <p>
    In December 2020, PostEra announced a multi-year strategic partnership with the pharma giant Pfizer to accelerate small molecule drug discovery. PostEra will develop a generative chemistry-based platform by utilizing Pfizer’s extensive data and expertise to be deployed across in-house, preclinical drug discovery programs. 
  </p>
</div>


PostEra

<div>
  <p>
    New York-based WorldQuant Predictive (WQP) develops an AI platform that caters to enterprise-level prediction challenges. Its proprietary predictive analytics platform, Quanto, utilizes machine learning to create models using databases and customer inputs to provide insights for decision-making. Quanto also uses Federated Learning capabilities to ensure privacy while giving clients access to third-party data without transferring ownership of datasets. The company says its platform can be applied across a range of industries, but the initial focus is on healthcare, retail, consumer goods, and financial services. 
  </p>
  <p>
    Founded in 2018, the company has partnered with healthcare providers including CPSI, a community healthcare solutions company. In February 2021, WorldQuant announced that it had developed a new AI-powered virtual screening tool that helps identify therapeutics from approved drugs to treat Covid-19. The tool was developed in collaboration with Chemical Abstracts Service (CAS), a division of the American Chemical Society.
  </p>
</div>


WorldQuant Predictive

<div>
  <p>
    PathAI is building an AI-based platform to assist pathologists in making rapid and accurate diagnoses for diseases such as cancer. Its platform uses convolutional neural networks in the analysis of medical images. This can also help in developing personalized medicines. 
  </p>
  <p>
    The company provides companion diagnostics (CDx) and biomarker development services to accelerate better diagnostics and drug discovery for targeted therapies. 
  </p>
  <p>
    Founded in 2016, the company is one of the most-funded companies in the digital pathology space. In May 2021, the company raised USD 165 million in Series C funding, bringing the company’s total funding up to more than USD 255 million. The company intends to use the cash to expand its product offerings and further develop its platform. The company has attracted investments from leading pharma companies Bristol-Myers Squibb and Merck Global Health Innovation Fund (Merck’s venture capital arm). 
  </p>
</div>


PathAI

<div>
  <p>
    Biodesix provides diagnostic solutions with a focus on lung diseases. It offers blood-based diagnostic products such as lung nodule tests in the lung cancer continuum of care. In addition, it also offers biopharma services such as biomarker discovery solutions using its proprietary artificial intelligence (AI) platform. This includes discovering novel biomarker tests, developing assays for known biological targets, gathering insights from patients' clinical studies, and enrolling patients into clinical trials. Its AI platform uses multiple technologies including genomics and transcriptomics as well as hundreds of different markers to design clinically useful tests. The company is a leading player in the lung-focused diagnostic testing market, having performed more than 200,000 diagnostic tests.
  </p>
  <p>
    In the biopharma services segment, Biodesix has partnered with large pharma companies such as Merck and Pfizer for biomarker development. In February 2020, it announced the completion of initial discovery. The company raised USD 23 million in Series G funding in May 2018, which the company intended to use for the expansion of its blood-based diagnostic tests for clinical use.
  </p>
</div>


Biodesix

<div>
  <p>
    Paige offers an artificial intelligence (AI)-powered pathology computational platform for detecting cancer subtypes, enabling pathologists to make accurate digital diagnoses. The company claims its deep learning algorithms have detected prostate cancer, skin cancer, and breast cancer accurately. Paige's platform can be used to access proprietary data to generate and test digital biomarker hypotheses, and Software-as-a-Service (SaaS)-based deployment of digital biomarkers to identify patients for therapies and clinical trials as well as cancer detection.
  </p>
  <p>
    Paige is the first company to receive the US Food and Drug Administration (FDA)’s breakthrough designation in 2019 for one of its pathology products, a prostate module. The company started commercializing its Paige Prostate from 2019, which is a first-to-market prostate cancer detection solution. Its AI solutions are vendor agnostic, which allows Paige to cater to a broad range of customers. It collaborated with Invicro LLC, a company providing radiology and diagnostic imaging services based in Canada, to provide AI-based integrated pathology solutions to the latter's drug discovery and development initiatives. The company closed a USD 125 million Series B funding in March 202 and plans to use the funds to expand its geographical presence and further develop its AI-powered clinical applications, biomarkers, and diagnostics.
  </p>
</div>


PAIGE

<div>
  <p>
    Glympse Bio is engaged in the development of synthetic biomarkers using its biosensor platform which could help in enhancing the understanding of human diseases and accelerate the drug discovery process. Its non-invasive biosensors are injectable into the human body to diagnose hidden diseases. As they pass through the diseased tissue, if certain enzymes and reactions related to the disease are present, it will leave a mark on the injected particle, which will then carry diagnostic signals out of the body when expelled through urine. The results from each patient are processed by a data engine that incorporates technologies including artificial intelligence (AI).
  </p>
  <p>
    The company’s main focus areas are non-alcoholic steatohepatitis (NASH) and oncology. In October 2019, Glympse Bio announced a strategic collaboration with Gilead to support the latter’s therapy programs in liver diseases. The company’s latest funding was closed in July 2020, where it raised USD 46.7 million in Series B financing. The proceeds will be used to secure the US Food and Drug Administration (FDA) approval for its technology as a medical device.
  </p>
</div>


Glympse Bio

<div>
  <p>
    Israel-based Ibex Medical Analytics is an AI-driven cancer diagnostics company helping physicians and healthcare professionals diagnose cancer in biopsies through its AI platform, Galen. 
  </p>
  <p>
    The company has deployed its cancer detection solutions, Galen Prostate and Galen Breast, which it claims are routinely used by pathologists to detect hard-to-diagnose cancers. The company is also partnering with drug manufacturers to develop AI-markers that can accelerate oncology drug development. Ibex combines data from digitized glass slides and electronic medical records with AI tools to find insights that can advance pathology and oncology research. 
  </p>
  <p>
    The company’s diagnostic solutions are deployed at Medipath, France-based private pathology labs, Maccabi’s Pathology Institute, Israel’s largest pathology lab, LDPath, a leading provider of digital pathology services to the National Health Service (NHS) in the UK, among others. Ibex is currently focused on growing its customer base in North America and Europe. The company entered into a partnership with an international diagnostics company Unilabs in July 2021 to deploy Ibex’s Galen platform in 16 European countries. Ibex has also entered into  partnerships with Philips, Sana Kliniken Berlin-Brandenburg, Indica Labs, and Proscia.
  </p>
  <p>
    The company has raised an aggregate of USD 51.6 million in private investments since its inception in 2016.
  </p>
</div>


Ibex Medical Analytics

AI SaaS | Biomarker Development

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

<div>
  <p>
    Visiopharm provides image analysis tools to help scientists, pathologists, and the biopharmaceutical industry support research, drug development, and diagnostics. The company's artificial intelligence (AI)-powered image analysis software for research is targeted at scientists and enables tissue mining to develop new treatments. It also provides AI-driven pathology solutions to facilitate precise diagnostics for pathologists. The company operates in more than 40 countries and has offices in Denmark, Sweden, the UK, Germany, and the US.
  </p>
</div>


Visiopharm

<div>
  <p>
    Emerald Cloud Labs offers a cloud lab that allows scientists to conduct lab research without requiring a physical laboratory. Its labs are built incorporating robotics and artificial intelligence (AI). Researchers can send samples to a lab and remotely design and conduct experiments. Its platform also organizes data to generate insights about the conducted experiments and analyze results. The company claims this allows researchers to focus on intellectual contributions rather than manual labor. Its lab includes over 150 lab instruments including liquid handlers, DNA synthesizers, microscopes, etc.
  </p>
  <p>
    The company is a leading player in the cloud laboratories space. It allows pharma companies to design and run their preclinical experiments. The company’s customer base has not been made public. The company raised USD 42.7 million in Series B financing in April 2019, bringing the total funding to USD 92.1 million.
  </p>
</div>


Emerald Cloud Lab

<div>
  <p>
    Synthace operates a cloud-based software platform to automate therapeutic development. Its platform combines both digital and physical aspects of drug development. Digital refers to the use of artificial intelligence (AI) to design and simulate biological systems and collate, structure, and analyze experimental data, while physical means automating lab systems to allow biological experimentation.
  </p>
  <p>
    Synthace collaborated with Oxford BioMedica in 2017 to design and experiment with gene and cell therapies. It has also worked with the Cell and Gene Therapy Catapult. The company is also working with large companies such as GSK, Merck, and Dow AgroSciences.
  </p>
</div>


Synthace

<div>
  <p>
    BenchSci uses AI to search, extract and display the relevant information required by scientists faster to help reduce experimental failure. It aims to help scientists select the right antibodies and reagents to conduct their preclinical experiments by significantly cutting down on the selection process, traditionally done by trial and error, from 12 weeks to 30 seconds, according to the company. The company claims a scientist can narrow down a possible 5,000 or so antibodies or reagents to just two or three, along with the scientific data and the experimental results that the specific antibody or reagent has generated. By doing so, waste can be reduced by some 70% as per BenchSci, thereby saving millions of dollars in costs.
  </p>
  <p>
    First launched as an AI-Assisted Antibody Selection in July 2017, the platform does this by accessing scientific papers and reagent catalogs to extract the relevant data points using machine learning tools and then build relationships between the data points. The results are then presented in a concise way in a searchable interface. The company claims to have more than 41,000 platform users (from over 4,000 institutions), having identified close to 20 million reagent use cases. In early 2020, the company raised USD 22 million in Series B funding to expand its clientele from academic institutions and big pharma to biotechs by rolling out a broader reagent selection platform.
  </p>
</div>


BenchSci

AI SaaS | Preclinical Experiments

<div>
  <p>
    Berkeley Lights operates a proprietary platform built with advanced automation to analyze live cells as well as application and workflow software to deliver robust single-cell data. Its platform enables users to perform rapid functional characterization of thousands of single cells in parallel while controlling the environment around each cell. It also offers a data library for every single cell which can be aggregated and analyzed by users digitally. This allows users to identify the best candidates and rapidly advance them while saving research and development (R&D) expenditures on poorly performing cells. It aims to focus mainly on antibody therapeutics, cell therapy, and synthetic biology.
  </p>
  <p>
    In 2017, Bayer collaborated with Berkeley Lights to identify antibodies and accelerate the development of cell lines. It is also working with Amgen on antibody discovery. As of 2019, the company's customer base comprised 45 customers, including eight of the 10 big pharma companies. Berkeley Lights started trading on the Nasdaq Global Select Market in July 2020, raising USD 205 million in gross proceeds via its IPO. It recorded an 81% YoY growth in revenue to USD 56.7 million in 2019 with net losses increasing by 27.5% YoY to USD 23.3 million. The growth in revenue is attributed to the significant increase (almost double) in both the adoption of Berkeley's platform by new users (22 new customers in 2019, up from 16 in 2018) and increased workflow utilization from existing customers.
  </p>
</div>


Berkeley Lights

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

<div>
  <p>
    Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.
  </p>
</div>


Arctoris

<div>
  <p>
    VERISIM Life provides a machine learning-driven platform to enable biosimulation models that reflect interactions between drugs and animals' biological systems. This could reduce the time spent on animal trials for pharma companies or even eliminate it.
  </p>
</div>


VeriSIM Life

<div>
  <p>
    XtalPi is an American-Chinese company operating Intelligent Digital Drug Discovery and Development (ID4) platform that uses artificial intelligence (AI), quantum physics, and high-performance cloud computing algorithms. It provides predictions on physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection and other aspects of drug development. 
  </p>
  <p>
    The company offers three software services: 1) XtalForce, a visual force field calculation software for molecule simulation, 2) XtalVision, a smart tool that delivers crystal structure prediction Reports, and 3) Renova, a platform used by the XtalPi AI Research Center (XARC) to support its AI drug R&D efforts.
  </p>
  <p>
    The company’s head office is based in Boston while its research and development (R&D) center, AI research center and an experimental center are in China. Its high-performance computing (HPC) cloud can deploy up to one million cores across Amazon Web Services (AWS), Tencent Cloud, Google Cloud and Alibaba Cloud.
  </p>
  <p>
    The company has collaborated with various pharmaceutical companies including  a partnership with Pfizer to develop a hybrid physics and AI software platform for accurate molecular modeling and with Porton Pharma Solutions, a contract development and manufacturing organization (CDMO), to initiate research in drug crystallization, intelligent drug discovery, and development research as well as business expansion in biologics and formulation. The company has also attracted investments from Google, Tencent, and Sequoia China.
  </p>
  <p>
    In August 2021, the company raised USD 400 million in a Series D funding round, reportedly ahead of a potential initial public offering (IPO).  The proceeds were earmarked for corporate expansion plans. XtalPi has raised an aggregate of USD 786.4 million in private investments since it was founded in 2014. 
  </p>
</div>


XtalPi

<div>
  <p>
    Insitro is an artificial intelligence (AI) drug discovery company founded by Daphne Koller, co-founder of Coursera, an online education platform. Its approach is based on test tube experiments, involving cells outside the human body, to predict what drug developers would see in a human clinical model. Using this method, it creates models of genetic diseases and applies AI to find differences between healthy and sick cells.
  </p>
  <p>
    Insitro aims to be a drug development company, making its own branded drugs, however, it also aims to partner with pharma companies on some drugs. While it has yet to discover a drug, the company entered into its first partnership in April 2019 with Gilead. The three-year collaboration aims to find new drugs to treat nonalcoholic steatohepatitis (NASH), a form of fatty liver disease. The company received USD 15 million in upfront fees, it will receive USD 35 million in near-term operational milestones and USD 200 million for each of the five programs Gilead pursues. Insitro raised Series C financing of USD 400 million in March 2021. It aims to use the funding to further develop its AI platform's capabilities and advance its drug pipeline. 
  </p>
</div>


Insitro

<div>
  <p>
    London-based Benevolent AI operates a proprietary drug discovery platform with four key interconnected areas of focus: Knowledge, Target Identification, Molecular Design, and Precision Medicine, covering the entire journey of the drug development process. The company claims it can shorten the time required for the early stages of the drug discovery process by 60%. The company’s current strategy is to partner with larger pharmaceutical players to jointly discover drug compounds for common disease types such as Alzheimer’s and other neurological diseases. It also aspires to build up its own portfolio of drugs (particularly in the area of rare diseases) and eventually commercialize successful drug candidates independently. The company has entered into partnerships with pharma giants Novartis and AstraZeneca.
  </p>
  <p>
    Benevolent AI has repurposed Baricitinib (along with Eli Lilly) as a potential treatment for Covid-19, and received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020. The company claims the process of tracing Baricitinib as a drug candidate took 90 minutes of computing time and an additional three days of human effort. In its latest funding round in September 2019, the company raised USD 90 million and was valued at USD 1 billion (half of the previous round valuation of USD 2 billion).
  </p>
</div>


BenevolentAI

<div>
  <p>
    AbSci operates SoluPro, a protein discovery and printing platform for designing soluble complex proteins and cell lines in a single efficient process. The company claims this approach reduces the drug discovery and development timelines from years to weeks. 
  </p>
  <p>
    AbSci has collaborated with leading pharma companies on 28 projects for drug development. In January 2021, it acquired AI startup Denovium Inc. to leverage the latter’s capabilities in drug discovery and cell line development. AbSci will integrate Denovium’s AI-based platform, capable of interpreting and predicting the behavior of proteins, with its Protein Printing platform. In June 2021, the company acquired Totient Inc., to leverage its target discovery capabilities and target antigen library for therapeutic protein design and training sets for deep learning models. The acquisitions will help the company speed up the drug development process by enabling in silico (computer-simulated) protein designing and optimization. 
  </p>
  <p>
    Previously based in Washington, AbSci shifted to Vancouver in 2016. The 170-person company also has offices in Cambridge, Massachusetts, and Serbia, and staff in the United Kingdom.
  </p>
  <p>
    The company went public on the Nasdaq under the ticker symbol “ABSI” in July 2021, raising around USD 230 million at an initial market capitalization of about USD 2 billion. AbSci has raised USD 237.9 million in private funding since its inception in 2011.
  </p>
</div>


AbSci

<div>
  <p>
    Atomwise is an artificial intelligence (AI) drug discovery company that uses a deep convolutional neural network (a deep learning tool used in facial recognition and self-driving cars) for drug discovery and design. The company claims it is the first in the sector to use this technology. Atomwise’s approach is focused on the chemistry aspect of the process. Its platform self-learns the organic chemistry behind the binding profiles and patterns and is capable of identifying hit compounds 10,000 times faster than traditional physical screening and 100 times faster than ultra-high-throughput screening. Its platform has been able to help in the discovery of potential lead compounds for more than 50 disease targets since 2012. In April 2020, in partnership with the world’s largest chemical supplier, Enamine Ltd, Atomwise conducted the world’s first and largest screening of 10 billion compounds to unearth novel leads to treat pediatric cancers. The company’s key therapeutic focus is on infectious diseases, neuroscience, and oncology.
  </p>
  <p>
    The company has expanded its original niche focus of using machine learning to predict binding profiles for small molecules to applying deep learning AI technology across all stages of preclinical drug discovery. It has formed multiple collaborations with academic research units, biopharmaceutical companies, and startups across the globe on more than 500 different drug discovery projects. The multi-year partnership established with Eli Lilly in June 2019 is prominent, seeking to discover up to 10 promising leads for targets selected by Eli Lilly. This lucrative deal provides Atomwise with USD 1 million in discovery milestones for each target and a further potential development and commercialization milestone of USD 550 million for all targets. In the latest funding round of August 2020, the company raised USD 123 million in Series B financing. It plans to use the funding to scale its AI platform and team.
  </p>
</div>


Atomwise

<div>
  <p>
    Dyno Therapeutics, a Massachusetts-based biotechnology company that relies on artificial intelligence (AI), operates the artificial intelligence (AI)-powered platform CapsidMap to discover and design novel gene therapies. Its platform is capable of optimizing adeno-associated viruses (AAV), widely-used vectors for gene therapies, by overcoming several naturally occurring limitations and building large synthetic AAVs to find enhanced gene therapy vectors that have great potential.
  </p>
  <p>
    Founded in 2018, Dyno Therapeutics raised USD 100 million in a Series A funding round in May 2021. The company has collaborations with Novartis, Sarepta, Roche, and Spark to improve tissue targeting, immune evasion, packaging size, and manufacturability.
  </p>
</div>


Dyno Therapeutics

<div>
  <p>
    Based in Ireland, Nuritas is engaged in the identification of therapeutic peptides (smaller versions of proteins) using artificial intelligence (AI) and genomics. Its main focus is on finding food derived from natural (mostly plant) bioactive peptides that can be used in a range of products including medical foods, pharmaceuticals, and dietary supplements. The company’s AI platform contains information on billions of peptides that the company has collated since its inception. Nuritas makes revenue by licensing its pipeline candidates to customers for further development and commercialization. The company has collaborated with companies such as BASF (the largest chemical producer in the world) and Nestle to discover new natural compounds that can form the basis of new foods, drugs, and nutritional supplements. BASF intends to market one of Nuritas’ products that is aimed at reducing inflammation to various product makers, such as producers of sports bars and nutritional supplements.
  </p>
  <p>
    The company has nine products in its pipeline with two–those focused on muscle health and skin health–in the commercialized stage, while a product targeted at metabolism is in the clinical stage. Its platform has also identified a novel peptide that demonstrates activity against a multi-modal fibrosis target. The company's latest funding round was in November 2018, where it raised EUR 30 million (approximately USD 33.9 million) backed by the European Investment Bank.
  </p>
</div>


Nuritas

<div>
  <p>
    California-based Entos provides molecular and materials discovery tools and designs small-molecule therapeutics combining machine learning and automated chemistry via its AI-driven platform OrbNet. The platform incorporates molecular simulations using quantum mechanics, molecular synthesis, and modeling. 
  </p>
  <p>
    The company’s technology is derived from Caltech and the University of Bristol and aims to accelerate the molecular discovery and design process. Entos claims it increases the speed and accuracy of molecular properties prediction by a thousand times without the need for custom supercomputers. Additionally, the company claims to reduce computational costs and the quantity of training data required by 100 times. It has already secured partnerships with a variety of companies in the pharmaceuticals, materials, and chemicals industries. 
  </p>
  <p>
    In addition to OrbNet, the company offers two other services: Entos Envision and Entos Sierra. Entos Envision is an open-source machine learning tool provided free of charge via the cloud to help scientists simulate and predict molecular structures without expert training. Entos Sierra provides a uniform Python application programming interface (API) for quantum simulations such as workflows, energy calculations, and dynamics.
  </p>
  <p>
    Founded in 2019, the company raised USD 53 million via an oversubscribed Series A funding round in July 2021. The proceeds will be directed toward developing the OrbNet platform and integrating it with robotic synthesis and high-throughput experimentation. 
  </p>
</div>


Entos

<div>
  <p>
    Empirico is a biotech firm that offers a precision insights platform for drug discovery using human genetics, data science, and programmable biology. It uses statistical and machine learning algorithms on large datasets to examine the role of genes and proteins in health and disease to discover high confidence therapeutic hypotheses. The company claims one of its advantages to be its dataset, which has been generated from “thousands of studies and millions of individuals” and to be one of the largest datasets of its kind globally.
  </p>
  <p>
    In January 2020, it announced a three-year collaboration with Ionis Pharmaceuticals (a biotechnology company that specializes in discovering and developing RNA-targeted therapeutics) where Empirico will use its platform to determine therapeutic targets which are responsive to antisense technology. Empirico secured USD 10 million in equity investment from Ionis, and will also receive up to USD 30 million based on the achievement of certain operational and preclinical milestones. In addition, Empirico could receive more than USD 620 million by achieving clinical development, regulatory and commercial milestones, plus royalties on net sales.
  </p>
</div>


Empirico

<div>
  <p>
    BigHat Biosciences provides a platform that combines artificial intelligence (AI) and a high-speed wet lab to design antibodies, enabling drug developers to speed up the discovery of therapeutics. The company claims its proprietary wet lab can synthesize, express, purify, and characterize hundreds of antibodies in days. Its AI systems guide each experiment to design therapeutic antibodies.
  </p>
</div>


BigHat Biosciences

<div>
  <p>
    Cyclica operates a structure-based, artificial intelligence (AI)-powered platform that aims to help design molecules minimizing unwanted off-target effects. For this purpose, the company offers two products: Ligand Design and Ligand Express, both of which will provide insights on molecules' activity through integrated systems and pharmacogenomics (the study of a genome's role in drug response). Cyclica works in partnership with biotech companies, academics, and pharma players with an aim to create 300 drug discovery programs across multiple therapeutic areas over the next two to three years and up to 1,000 programs over the next decade.
  </p>
  <p>
    As of June 2020, the company had 30 active drug discovery programs with big pharma players such as Merck KGaA and Bayer (who pay upfront fees and milestone payments) and other institutions such as NineteenGale Therapeutics, Genome Institute of Singapore, and the University of Toronto.
  </p>
</div>


Cyclica

<div>
  <p>
    Spring Discovery provides a drug discovery platform based on machine learning which specializes in discovering therapies to treat biological damage accumulated through aging. The company has the capabilities to run full experiments on biological materials such as human cells and mice. Spring Discovery was founded by a former lead engineer of Khan Academy. The leadership and advisory teams of the company include scientists from universities such as Harvard and Stanford and professionals from companies such as Google, Amgen, and OpenAI.
  </p>
</div>


Spring Discovery

<div>
  <p>
    Tara Biosystems is a company that focuses on cardiac drug discovery. Its Biowire platform generates cardiac tissue that replicates the characteristics of the human heart (in-vitro biology). The company uses these tissues to help pharma companies test drugs, run simulations, and accurately identify cardiovascular complications without having to test on animals or actual humans. The platform can be used through all aspects of the drug discovery process, including target validation, compound optimizations, and preclinical assessments.
  </p>
  <p>
    Tara Biosystems partnered with VantAI in July 2020 allowing the partnership to leverage Tara's in-vitro human biology models and VanAI's computational drug discovery capabilities to develop new therapies for cardiac diseases.
  </p>
</div>


Tara Biosystems

AI SaaS | Drug Discovery

<div>
  <p>
    Based in Canada, AbCellera is an artificial intelligence (AI) drug discovery company focused on finding therapeutic antibodies that can be used as a treatment for various diseases, including cancer, neurodegeneration, and infections such as influenza and Covid-19. 
  </p>
  <p>
    The company claims the main advantage of its antibody discovery platform is the use of a combination of methods to identify drug targets. Prior to the outbreak of the pandemic, it worked with the Defense Advanced Research Projects Agency (DARPA) to establish a robust pandemic response plan and develop countermeasures within 60 days. The company has experimented with more than 60 million immune cells from multiple patient samples and identified over 2,000 unique human antibodies that bind to the surface of the Covid-19 virus. AbCellera has established partnerships with Eli Lilly, GSK, Novartis, Pfizer, Sanofi, and Teva Pharmaceutical Industries. In July 2021 the company teamed up with EQRx and Tachyon therapeutics, to develop novel therapeutic antibodies for oncology and immunology areas.
  </p>
  <p>
    AbCellera gained worldwide popularity after discovering a Covid-19 antibody treatment, Bamlanivimab, in partnership with the pharma giant Eli Lilly, and gained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). The company identified the neutralizing antibody against the virus in March 2020 and accelerated the process from screening to clinical testing in 90 days. 
  </p>
  <p>
    AbCellera started trading on the NASDAQ Exchange from December 2020. From the nine months to September 2020, the company reported revenue of USD 25.2 million (USD 8.4 million for the corresponding period in 2019) and net income of USD 1.9 million (net loss of USD 570,000 for the corresponding period in 2019).
  </p>
</div>


AbCellera Biologics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

<div>
  <p>
    Arzeda employs a computational-based technology platform to design new and improved proteins. The company claims its protein design technology maximizes the probability of commercial success by ensuring the selection of proteins and enzymes compatible with production host and engineering for protein stability, enzyme selectivity, and high expression. Its protein design can be used in diagnostic applications such as the development of non-immunogenic therapeutic enzymes and other enzymes for human diagnostic applications. The company also provides solutions for agriculture (to improve plant health and yield), functionalized sweeteners (enzymes for production for sugars and natural sweeteners), and industrial chemicals.
  </p>
  <p>
    The company has seen demand in a range of industries, establishing partnerships with companies such as DuPont Pioneer (on enzymes to improve seed performance) and Invista (to create the building blocks of nylon). Government agencies such as the National Science Foundation, the US Department of Agriculture (USDA), Defense Advanced Research Projects Agency (DARPA), and the Department of Energy have made investments in the company.
  </p>
</div>


Arzeda

<div>
  <p>
    Jerusalem-based Pepticom uses biocomputational AI software to design novel peptide drug candidates that speed up the drug development process while reducing risks and costs. The company claims its technology is capable of screening 1,030 possible molecular options—higher than other screening techniques—to find suitable candidates. The company has several undisclosed in-house programs at the discovery stage and has also entered into partnerships with the agricultural firm Adama, the University of Oxford, The Hebrew University of Jerusalem, and Fraunhofer. 
  </p>
</div>


Pepticom

<div>
  <p>
    NuMedii provides a drug discovery platform that uses artificial intelligence (AI) and big data to accelerate precision therapies. Its platform facilitates the exploration of favorable “poly-pharmacology” profiles that can potentially improve therapeutic efficacy by modulating effects on multiple disease pathways. NuMedii has multiple active research and development (R&D) collaborations with global pharmaceuticals and biotech giants for drug discovery, target discovery, and biomarker identification across therapeutic areas of oncology, inflammation, and rare diseases.
  </p>
</div>
